Ann: Half Yearly Report and Accounts, page-7

[Events since the end of the financial yearNo matter or circumstance has arisen since 31 December 2018 that has significantly affected the Group'soperations, results or state of affairs, or may do so in future periods.]

Pixi, we know the result on antibiotic resistant bacteria treatment for PBT2 happened before Dec 31 and the Life deal was also before Dec 31.

The statement on that new PBT2 development I guess is:
[PBT2 Huntington disease clinical development updatePrana is continuing to review its options to either undertake additional non-clinical studies in the dog, pursuedevelopment opportunities at dosing levels permitted by the FDA, or pursue alternative therapeutic applicationsof PBT2.]

Persue? One must hope that is true. This situation reminds me of the CQ patent problem. Prana called in the manufacturer of CQ, Gerolymatos, for whatever reason, and  Gerolymatos lodged a patent to cover AD use, leaving Prana to fight it out in the courts for the IP. As we now know Prana got the US and Japan and Gerolymatos got Europe and the rest for CQ. In the meantime Prana developed PBT2, which was considered a much better drug. Now we are left to wonder weather something in the inverse is happening here. All just speculation of course because holders are being treated like mushrooms, but at least Prana have some experience here, fighting for a patent in US courts, as the discoverer of the new indication for the old drug.
All above IMHO. DYOR.https://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=text&issuerId=4287&announcementId=451172&documentDate=2002-01-07&documentNumber=185658